Trial reportJMA journal2026
Impact of Cardio-cerebrovascular Diseases on Enzalutamide and Abiraterone Treatment in Castration-resistant Prostate Cancer.
Trial report in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The ENABLE study demonstrated comparable survival benefits between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) in castration-resistant prostate cancer (CRPC). Although the association between androgen receptor signaling inhibition and cardio-cerebrovascular diseases (CCVDs) has long been discussed, definitive evidence remains limited. We evaluated the efficacy of these agents in patients with CRPC who have CCVDs. Methods: This investigator-initiated, multicenter, randomized controlled trial allowed enrollment of patients with prior or concurrent CCVDs. Prespecified end points included time to prostate-specific antigen (PSA) progression (TTPP), radiographic progression-free survival (rPFS), overall survival (OS), prostate cancer-specific survival (PCSS), and safety. Outcomes were compared between patients with and without CCVDs (CCVD- vs CCVD+) and between treatment arms within each group. Results: The CCVD- group included 142 patients (75 ENZ and 67 ABI), and the CCVD+ group included 36 patients (14 ENZ and 22 ABI). The most frequent CCVD was cerebral infarction (n = 11, 31%). Survival outcomes did not differ significantly between patients in the CCVD- group and those in the CCVD+ group (median TTPP 15.2 vs 21.2; p = 0.8001; rPFS 18.1 vs 9.4; p = 0.0971; OS 37.4 vs 30.5; p = 0.1793; PCSS 46.8 vs 32.1; p = 0.6348). Within both groups, ENZ and ABI showed no significant differences in TTPP, rPFS, OS, or PCSS. Adverse event rates were also comparable across CCVD groups and treatment arms. Conclusions: Patients with CCVDs showed no significant differences in survival or safety compared with those without CCVDs, and ENZ and ABI produced similar outcomes in both groups. These findings indicate that both agents remain feasible options irrespective of CCVD history. Public trials registry: The trial was registered with the University Hospital Medical Information Network (UMIN) Center under the identifier UMIN000015529 on November 1, 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.